Update on Pathogenesis and Treatment of Kaposi’s Sarcoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (5 April 2024) | Viewed by 1175
Special Issue Editor
2. Dermatology Unit – Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Pace, 9, Milan, Italy
Interests: Kaposi’s sarcoma; HHV8-associated malignancies; dermoscopy
Special Issue Information
Dear Colleagues,
Kaposi’s sarcoma is a rare, low-grade vascular neoplasm that is caused by Human Herpes Virus 8 (HHV-8) infection. In addition to HHV-8 infection, other factors are required in order to develop the disease, with the most important being impaired host immunity. Only a small number of infected subjects will develop Kaposi’s sarcoma, and patients with acquired immune deficiency syndrome or under immune suppressive treatments are more likely to develop this neoplasm.
Since the discovery of HHV-8 in 1994, much has been learned about its epidemiology; however, many aspects regarding pathophysiology and their application into clinical practice are not yet fully clarified. Indeed, in the era of immunotherapy and targeted therapies for different types of cancer, chemotherapy is still the most common modality of treatment for patients with Kaposi’s sarcoma.
This Special Issue will focus on the latest research results that contribute to the pathogenesis of Kaposi’s sarcoma and its management and outcomes. Original research or review articles are welcome.
Dr. Athanasia Tourlaki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Kaposi’s sarcoma
- Human Herpes Virus 8 (HHV-8)
- oncogenesis
- chemotherapy
- targeted therapy
- immunotherapy
